Magnevist
(Gadolinium)Phase 2Small molecule
Gadolinium is a contrast agent used during MRI scans to help doctors see certain body structures and tissues more clearly by making them appear brighter in the images.[1] Magnevist is currently being investigated across 11 indications[3], with its most advanced program in Phase 2.[1]
Magnevist is one of 268 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
11
Indications
29
Total Trials
7
Active Trials
267
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Zoladex
TTerSera Therapeutics LLC
Phase 3
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Verzenio
Eli LillyPhase 3
Ritalin
NovartisPhase 3
Acetylsalicylic Acid
BayerPhase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
Magnevist
OOHSU Knight Cancer Institute
Phase 2
Semaglutide Pen Injector
UUniversitaire Ziekenhuizen KU Leuven
Phase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Brain Tumors4 trials
Glioblastoma2 trials
Glioblastoma Multiforme2 trials
19 more indications
Prostate Cancer1 trial
Chronic1 trial
Chronic Convection Enhanced Delivery of Topotecan
Completed·—·Phase 1·NCT03154996·5 enrolled
Acute Myeloid Leukemia1 trial
Pilot Study1 trial
Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study
Completed·—·Phase 1·NCT02783768·12 enrolled
AIN1 trial
Epilepsy1 trial
Central Nervous System Neoplasm1 trial
Brain Metastases1 trial
LMS - Leiomyosarcoma1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gadolinium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- OOHSU Knight Cancer Institute